Evidence map›Paper›PMID 40475092›Full record

ArticleJournal of hepatocellular carcinoma2025

Predicting Resistance and Survival of HCC Patients Post-HAIC: Based on Shapley Additive exPlanations and Machine Learning.

Fan Yao, Jianliang Miao, Bing Quan, Jinghuan Li, Bei Tang, Shenxin Lu, Xin Yin

Abstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fan Yao *Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Jianliang Miao *First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, People's Republic of China.
Bing QuanLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Jinghuan LiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Bei TangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Shenxin LuLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Xin YinLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To establish prediction models using Shapley Additive exPlanations (SHAP) and multiple machine learning (ML) algorithms to identify clinical features influencing hepatic arterial infusion chemotherapy (HAIC) resistance and survival in patients with hepatocellular carcinoma (HCC). Patients and Methods: We recruited 286 patients with unresectable HCC who underwent HAIC. Patients were divided into training and validation datasets (7:3 ratio). eXtreme Gradient Boosting (XGBoost) was used to build the preliminary resistance prediction model. The SHAP values explained the importance of the clinical features. Recursive Feature Elimination with Cross-Validation (RFECV) was used to select the optimum number of features. Seven ML methods were used to construct further resistance prediction models, and ten ML algorithms were employed to establish the survival prognosis models. Results: The areas under the curve (AUC) of the XGBoost model were 1.000 and 0.812 for the training and validation groups, respectively. SHAP identified 27 of the 38 clinical features affecting resistance, with pre-HAIC treatment being the main factor. RFECV showed the best model performance with six features (pre-HAIC treatment, tumor size, HBV DNA, alkaline phosphatase (AKP), prothrombin time (PT), and portal vein tumor thrombosis (PVTT)). Random Forest had the best performance among the seven ML algorithms (AUC=0.935 for training, AUC=0.876 for validation). The combination of Stepcox [forward] and Gradient Boosting Machine was the best for predicting survival (AUC=0.98 in training, AUC=0.83 in validation). Based on the above clinical characteristics, patients were categorized into high-risk and low-risk groups based on the median risk score, and it was found that these characteristics also performed well in the prognostic model for predicting the survival of patients with HCC. Conclusion: Pre-HAIC treatment, tumor size, HBV DNA, AKP, PT, and PVTT are effective predictors of post-HAIC resistance and survival in patients with unresectable advanced HCC.

Indexed as

hepatocellular carcinoma outcomesinterpretable AIprognostic modelingtreatment response prediction

Identifiers

PMID40475092
PMCPMC12140075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.